LENZ Therapeutics (LENZ) grants CFO stock options and RSUs awards

Rhea-AI Filing Summary

LENZ Therapeutics Chief Financial Officer Daniel R. Chevallard received new equity awards. On January 2, 2026, he was granted a stock option for 84,200 shares of LENZ Therapeutics, Inc. common stock at an exercise price of $16 per share, with no cash paid for the option itself.

The filing also reports a grant of 14,000 restricted stock units, each representing one share of common stock. Both the option and RSUs vest over time starting from January 2, 2026, and vesting is conditioned on Mr. Chevallard continuing to serve as a Service Provider under the company’s 2024 Equity Incentive Plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chevallard Daniel R.

(Last) (First) (Middle)

C/O LENZ THERAPEUTICS, INC.

201 LOMAS SANTA FE DRIVE, SUITE 300

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LENZ Therapeutics, Inc. [ LENZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16	01/02/2026		A		84,200		(1)	01/01/2036	Common Stock	84,200	$0	84,200	D
Restricted Stock Unit	(2)	01/02/2026		A		14,000		(3)	(3)	Common Stock	14,000	$0	14,000	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean January 2, 2026.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

3. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the RSU Grant Date, and one eighth (1/8th) of the RSUs subject to the award shall vest every six (6) months thereafter on the same day of the month as the RSU Grant Date (and if there is no corresponding day, on the last day of the month). "RSU Grant Date" shall mean January 2, 2026.

Remarks:

	/s/ Daniel R. Chevallard	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did LENZ (LENZ) grant to its CFO Daniel R. Chevallard?

The CFO received a stock option for 84,200 shares of LENZ Therapeutics, Inc. common stock at an exercise price of $16 per share, and a grant of 14,000 restricted stock units, each representing one share of common stock.

When were the new LENZ (LENZ) CFO stock option and RSU grants made?

Both the stock option and the restricted stock unit awards to the LENZ Therapeutics Chief Financial Officer were granted on January 2, 2026.

How do the LENZ (LENZ) CFO stock options vest?

Subject to continued service as a Service Provider under the 2024 Equity Incentive Plan, 25% of the option shares vest on the one-year anniversary of the January 2, 2026 vesting commencement date, and the remaining shares vest in equal monthly installments over 36 months.

How do the LENZ (LENZ) CFO restricted stock units vest?

Subject to continued service as a Service Provider, 25% of the 14,000 RSUs vest on the one-year anniversary of the January 2, 2026 RSU grant date, and the remaining RSUs vest in equal installments every six months over the subsequent periods.

What does each LENZ (LENZ) restricted stock unit represent for the CFO award?

Each restricted stock unit granted to the CFO represents a contingent right to receive one share of LENZ Therapeutics, Inc. common stock, subject to the vesting conditions being met.

Is the LENZ (LENZ) CFO equity award held directly or indirectly?

The filing shows the CFO’s 84,200 stock options and 14,000 RSUs as directly owned, with no indirect ownership entity disclosed.